RPRX

SEC source: 0001802768-25-000023 · wk-form4_1745271779.xml · nonDerivative · entry 1

Coric Vlad · CIK 0001704317 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,184

F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-25-000017 · wk-form4_1743543999.xml · nonDerivative · entry 1

Bassler Bonnie L · CIK 0001683607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,440

F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001802768-25-000016 · wk-form4_1743543926.xml · nonDerivative · entry 1

Fernandez Henry A · CIK 0001416750 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,646

F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001802768-25-000012 · wk-form4_1739916980.xml · derivative · entry 3

Hite Christopher · CIK 0001814238 · EVP & Vice Chairman

10b5-1 filing: No plan indicated

Ownership: Indirect · By SCH Investment Partners LLC

Disclosed balance after: 86,641

Underlying: Class A Ordinary Shares · 300,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F2 · derivative.exercise_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value.

F2 · derivative.expiration_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value.

SEC source: 0001802768-25-000012 · wk-form4_1739916980.xml · nonDerivative · entry 1

Hite Christopher · CIK 0001814238 · EVP & Vice Chairman

10b5-1 filing: No plan indicated

Ownership: Indirect · By SCH Investment Partners LLC

Disclosed balance after: 600,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

SEC source: 0001802768-25-000006 · wk-form4_1735853350.xml · nonDerivative · entry 1

Bassler Bonnie L · CIK 0001683607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,299

F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001802768-25-000005 · wk-form4_1735853312.xml · nonDerivative · entry 1

Fernandez Henry A · CIK 0001416750 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,505

F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001802768-24-000055 · wk-form4_1727730521.xml · nonDerivative · entry 1

Bassler Bonnie L · CIK 0001683607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,796

F1 · price: 1. Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001802768-24-000054 · wk-form4_1727730460.xml · nonDerivative · entry 1

Fernandez Henry A · CIK 0001416750 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,002

F1 · balance_after: 1. Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001802768-24-000049 · wk-form4_1723504736.xml · derivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 79,200 shares

Expires not disclosed

F1 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.

F2 · kind: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

SEC source: 0001802768-24-000051 · wk-form4_1723504825.xml · derivative · entry 1

Coyne Terrance P. · CIK 0001814876 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · By TPC ICAI, LLC

Disclosed balance after: 44,350

Underlying: LP interests in RPI US Partners 2019, LP · 2,000 shares

Expires not disclosed

F1 · derivative.exercise_price: No ICAI Interests or limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. ICAI Interests represent a grant of an equivalent number of limited partnership interest in RPI US LP ("RPI US LP Interest"). Each RPI US LP Interest may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.

F2 · kind: The Reporting Person made a charitable donation of ICAI Interests. No Class A Ordinary Shares, RPI US LP Interests or ICAI Interests were sold.

F3 · derivative.exercise_date: Represents ICAI Interests. Each ICAI Interests represents a grant of an equivalent number of RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents ICAI Interests. Each ICAI Interests represents a grant of an equivalent number of RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

SEC source: 0001802768-24-000047 · wk-form4_1723504630.xml · derivative · entry 1

Urist Marshall · CIK 0001838139 · EVP, Research & Investments

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sandy Lamm LLC

Disclosed balance after: 126,412

Underlying: Class A Ordinary Shares · 21,820 shares

Expires not disclosed

F1 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.

F2 · kind: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

SEC source: 0001802768-24-000042 · wk-form4_1719609121.xml · nonDerivative · entry 1

Fernandez Henry A · CIK 0001416750 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,660

F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001802768-24-000040 · wk-form4_1719608984.xml · nonDerivative · entry 1

Bassler Bonnie L · CIK 0001683607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,454

F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001802768-24-000038 · wk-form4_1718050892.xml · nonDerivative · entry 1

Norden Gregory · CIK 0001405104 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,738

F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-24-000035 · wk-form4_1718050587.xml · nonDerivative · entry 1

LOVE TED W · CIK 0001188919 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,234

F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-24-000033 · wk-form4_1718050517.xml · nonDerivative · entry 1

HODGSON DAVID C · CIK 0001193346 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,714

F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. The restricted stock units granted to the reporting person are held by him solely for the benefit of General Atlantic Service Company, L.P. The reporting person disclaims beneficial ownership of the restricted stock units and the underlying shares.

SEC source: 0001802768-24-000031 · wk-form4_1718050428.xml · nonDerivative · entry 1

Fernandez Henry A · CIK 0001416750 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,261

F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-24-000029 · wk-form4_1718050336.xml · nonDerivative · entry 1

Engelbert Catherine M. · CIK 0001796439 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,514

F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-24-000027 · wk-form4_1718050260.xml · nonDerivative · entry 1

DESOUZA ERROL B · CIK 0001213895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,738

F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-24-000025 · wk-form4_1718050174.xml · nonDerivative · entry 1

Bassler Bonnie L · CIK 0001683607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,055

F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-24-000023 · wk-form4_1715895759.xml · derivative · entry 2

Hite Christopher · CIK 0001814238 · EVP & Vice Chairman

10b5-1 filing: No plan indicated

Ownership: Indirect · By SCH Investment Partners LLC

Disclosed balance after: 541

Underlying: Class A Ordinary Shares · 300,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F3 · derivative.exercise_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Royalty Pharma Holdings, Ltd. ("Holdings") at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value.

F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 928,800 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.

SEC source: 0001802768-24-000023 · wk-form4_1715895759.xml · nonDerivative · entry 1

Hite Christopher · CIK 0001814238 · EVP & Vice Chairman

10b5-1 filing: No plan indicated

Ownership: Indirect · By SCH Investment Partners LLC

Disclosed balance after: 370,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 928,800 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.

SEC source: 0001802768-24-000018 · wk-form4_1712093434.xml · nonDerivative · entry 1

Fernandez Henry A · CIK 0001416750 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,968

F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001802768-24-000016 · wk-form4_1712093313.xml · nonDerivative · entry 1

Bassler Bonnie L · CIK 0001683607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,762

F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001802768-24-000014 · wk-form4_1708647785.xml · derivative · entry 4

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 270,000

Underlying: Class A Ordinary Shares · 30,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F2 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F2 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

SEC source: 0001802768-24-000014 · wk-form4_1708647785.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,099

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

SEC source: 0001802768-24-000002 · wk-form4_1704406578.xml · nonDerivative · entry 3

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,099

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.36 to $27.79 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001802768-24-000002 · wk-form4_1704406578.xml · nonDerivative · entry 2

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,801

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.48 to $28.26 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001802768-24-000002 · wk-form4_1704406578.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 254,899

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.97 to $28.79 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001802768-23-000036 · wk-form4_1703888031.xml · nonDerivative · entry 1

Fernandez Henry A · CIK 0001416750 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,728

F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001802768-23-000035 · wk-form4_1703887896.xml · nonDerivative · entry 1

Bassler Bonnie L · CIK 0001683607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,522

F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001140361-24-000455 · form4.xml · nonDerivative · entry 1

Avara Management Ltd · CIK 0001814934 · 10% owner

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,477,520

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.105 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Reflects securities held directly by Avara Management Ltd. Avara Management Ltd is wholly-owned by M. Germano Giuliani.

F3 · ownership.nature: The Reporting Person may be deemed to beneficially own the securities reported herein directly or indirectly controlled by him, but such Reporting Person (other than the direct holder to the extent of his direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Person is the beneficial owner of any securities reported herein or is subject to Section 16.

SEC source: 0001140361-23-060204 · form4.xml · nonDerivative · entry 2

Avara Management Ltd · CIK 0001814934 · 10% owner

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,543,323

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.47 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Reflects securities held directly by Avara Management Ltd. Avara Management Ltd is wholly-owned by M. Germano Giuliani.

F3 · ownership.nature: The Reporting Person may be deemed to beneficially own the securities reported herein directly or indirectly controlled by him, but such Reporting Person (other than the direct holder to the extent of his direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Person is the beneficial owner of any securities reported herein or is subject to Section 16.

SEC source: 0001140361-23-060204 · form4.xml · nonDerivative · entry 1

Avara Management Ltd · CIK 0001814934 · 10% owner

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,753,186

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.06 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Reflects securities held directly by Avara Management Ltd. Avara Management Ltd is wholly-owned by M. Germano Giuliani.

F3 · ownership.nature: The Reporting Person may be deemed to beneficially own the securities reported herein directly or indirectly controlled by him, but such Reporting Person (other than the direct holder to the extent of his direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Person is the beneficial owner of any securities reported herein or is subject to Section 16.

SEC source: 0001140361-23-058427 · form4.xml · nonDerivative · entry 1

Avara Management Ltd · CIK 0001814934 · 10% owner

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,794,915

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.03 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Reflects securities held directly by Avara Management Ltd. Avara Management Ltd is wholly-owned by M. Germano Giuliani.

F3 · ownership.nature: The Reporting Person may be deemed to beneficially own the securities reported herein directly or indirectly controlled by him, but such Reporting Person (other than the direct holder to the extent of his direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Person is the beneficial owner of any securities reported herein or is subject to Section 16.

SEC source: 0001140361-23-057897 · form4.xml · nonDerivative · entry 2

Avara Management Ltd · CIK 0001814934 · 10% owner

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,805,144

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.50 to $29.44 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Reflects securities held directly by Avara Management Ltd. Avara Management Ltd is wholly-owned by M. Germano Giuliani.

F4 · ownership.nature: The Reporting Person may be deemed to beneficially own the securities reported herein directly or indirectly controlled by him, but such Reporting Person (other than the direct holder to the extent of his direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Person is the beneficial owner of any securities reported herein or is subject to Section 16.

SEC source: 0001140361-23-057897 · form4.xml · nonDerivative · entry 1

Avara Management Ltd · CIK 0001814934 · 10% owner

Giuliani Mario Germano · CIK 0001814882 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,169,585

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.52 to $29.34 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Reflects securities held directly by Avara Management Ltd. Avara Management Ltd is wholly-owned by M. Germano Giuliani.

F4 · ownership.nature: The Reporting Person may be deemed to beneficially own the securities reported herein directly or indirectly controlled by him, but such Reporting Person (other than the direct holder to the extent of his direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Person is the beneficial owner of any securities reported herein or is subject to Section 16.

SEC source: 0000950103-23-016404 · dp202859_4-legorreta.xml · nonDerivative · entry 2

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,795

F1 · kind: Represents the transfer by the Reporting Person of Class A ordinary shares for no consideration to RP Management Equity Incentive Plan Trust.

F2 · balance_after: Reflects the exempt transfer pursuant to Rule 16a-13 of Class A ordinary shares from the GST-Exempt Legorreta 2012 Family Trust.

SEC source: 0001802768-23-000032 · wk-form4_1700008499.xml · derivative · entry 8

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 162,680

Underlying: Class A Ordinary Shares · 100,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,096 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.

SEC source: 0001802768-23-000032 · wk-form4_1700008499.xml · derivative · entry 7

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 245,299

Underlying: Class A Ordinary Shares · 50,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,096 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.

SEC source: 0001802768-23-000032 · wk-form4_1700008499.xml · nonDerivative · entry 2

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 220,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,096 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.

SEC source: 0001802768-23-000032 · wk-form4_1700008499.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 80,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,096 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.

SEC source: 0001802768-23-000030 · wk-form4_1700000224.xml · derivative · entry 4

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Class A Ordinary Shares · 47,559 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F2 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F2 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

SEC source: 0001802768-23-000030 · wk-form4_1700000224.xml · nonDerivative · entry 1

RIGGS RORY B · CIK 0001016835 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 490,099

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

SEC source: 0001209191-23-051475 · doc4.xml · nonDerivative · entry 1

Fernandez Henry A · CIK 0001416750 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,375

F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001209191-23-051471 · doc4.xml · nonDerivative · entry 1

Bassler Bonnie L · CIK 0001683607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,169

F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001209191-23-045463 · doc4.xml · nonDerivative · entry 2

Coyne Terrance P. · CIK 0001814876 · EVP & CFO

10b5-1 filing: Plan reported

Ownership: Indirect · By TPC RP 2021, LLC

Disclosed balance after: 790,000

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.55 to $31.07 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-045463 · doc4.xml · nonDerivative · entry 1

Coyne Terrance P. · CIK 0001814876 · EVP & CFO

10b5-1 filing: Plan reported

Ownership: Indirect · By TPC RP 2021, LLC

Disclosed balance after: 827,500

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.49 to $31.41 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-23-045063 · doc4.xml · derivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 55,550 shares

Expires not disclosed

F1 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.

F2 · kind: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.